Submission of Un-Audited Standalone Financial Results for the Quarter ended as on June 30, 2026

GODAVARI DRUGS LIMITED Regd. Off.:‘Mayfair’, S.P. Road, Secunderabad - 500 003. TS, India. Voice : +91-40-2784 9700 / 2784 2602 / 2784 4557 E-mail : info@godavaridrugs.com | Website : www.godavaridrugs.com 14.08.2026 The Manger [Listing] The BSE Limited The Secretary, Listing Department Phirozejeejeebhoy Towers, Dalal Street, Fort, Mumbai- 400001 Scrip code: 530317 Dear Sirs/Madam, Sub: Submission of Un-Audited Standalone and Consolidated Financial Results of the Company, for the quarter ended on 30th June 2026 as per the provisions of SEBI (lODR) Regulations, 2015 Please find the enclosed herewith the following documents in terms of Regulation 33 of SEBI (LODR) Regulations, 2015: 1. Un-Audited Standalone Financial Results of the Company for the first quarter ended 30th June 2026. 2. Limited Review Report on Standalone Financial results of the Company for the first quarter ended on 30th June, 2026 as required under Regulation 33 of SEBI (LODR) Regulations, 2015 These are also being made available on the website of the Company at www.godavaridrugs.com. The Board Meeting Commenced at 11.45 A.M and concluded at 12:30 PM Please take the above in your records. Thanking You, For Godavari Drugs Limited Venkatesh Achanta Company Secretary & Compliance Officer Plant : A-6/2, MIDC, Nanded - 431 603. MS, India. E-mail : nnd@godavaridrugs.comCIN:L24230TG1987PLC008016 GODAVARI DRUGS LIMITED CIN : L24230TG1987PLC008016 Regd Office : 'Mayfair" S.P.Road, Secunderabad STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026 Rupees in Lakhs Sl. Quarter ended Year ended Particulars No. 30.06.2026 31.03.2026 30.06.2025 31.03.2026 (Unudited) (Audited) (Unudited) (Audited) 1 Revenue from operations 2795.72 3316.31 2381.13 10580.81 2 Other Income 15.10 14.12 1.22 80.51 3 Total Revenue from operations (1+2) 2810.82 3330.43 2382.35 10661.32 4 Expenses (a) Cost of materials consumed 2614.88 3026.61 1798.93 8888.89 (b) Changes in inventories of finished goods & work-in-progress -634.45 -489.54 -85.41 -1139.13 (c) Employee benefits expense 147.68 132.05 135.67 569.66 (d) Depreciation & amortization expense 59.28 61.21 60.43 243.21 (e) Finance Costs 89.61 95.55 100.46 397.97 (f) Other Expenses 416.09 353.17 242.04 1229.93 Total expenses 2693.09 3179.05 2252.12 10190.53 5 Profit before exceptional Items and tax (3-4) 117.73 151.38 130.23 470.79 6 Exceptional items - 1 0.38 - 3 5.51 7 Profit before Tax (5+6) 117.73 161.76 130.23 506.30 8 Tax expense -6.82 -32.68 -26.17 -97.39 9 Net Profit for the period (7-8) 110.91 129.08 104.06 408.91 10 Other Comprehensive Income (i) Items that will not be reclassified to profit or loss - - - - (ii) Income tax relating to Items that will not be reclassified to profit or loss - - - - (iii) Items that will be reclassified to profit or loss - - - - (iv) Income tax relating to Items that will be reclassified to profit or loss - - - - Total Other Comprehensive Income (Net of Tax) - - - - 11 Total Comprehensive Income (9+10) 110.91 129.08 104.06 408.91 12 Paid-up equity share capital (Face Value Rs. 10/- per share) 1012.74 1012.74 753.05 1012.74 13 Other Equity as shown in the Audited Balance Sheet of the previous year - 6042.04 - 6042.04 14 Earnings per share (a) Basic 1.10 1.71 1.38 5.43 (b) Diluted 1.10 1.64 1.38 5.36 1) The above results , as reviewed by the Audit Committee, were considered, approved and taken on record by the Board of Directors at its meeting held on August 14, 2026. 2) The above results were prepared in accordance with Indian Accounting Standards (IND AS) prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable. 3) EPS of Current Quarter is based on paid up capital of Rs. 1012.74 Lacs as against Rs. 753.05 Lacs as of 30.06.2025. 4) The format for un-audited quarterly results as prescribed in SEBI’s Circular No. CIR/CFD/CMD/15/2015 dated 30th November, 2015 has been modified to comply with requirements of SEBI’s Circular dated 5th July, 2016. Ind AS Schedule III (Division II) to the Companies Act, 2013 applicable to companies that are required to comply with IND AS. 5) Corresponding figures in previsous year / period have been regrouped wherever considered necessary. For GODAVARI DRUGS LIMITED Mohit Jaju Place: Secunderabad Wholetime Director & CFO Date : 14.08.2026 DIN: 03405414